Head and Neck Cancer News

Advexin® Improves Survival in Head and Neck Cancer (07/29/2008)
The targeted agent Advexin (p53 tumor suppressor therapy) improves survival compared with methotrexate among head and neck cancer patients with the p53 biomarkers.  These results were recently presented at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine.

Acupuncture Reduces Pain After Surgery for Head and Neck Cancer (06/06/2008)
According to the results of a study presented at the 2008 annual meeting of the American Society of Clinical Oncology, acupuncture is more effective than usual care in reducing pain and dysfunction following neck dissection (surgical removal of lymph nodes on side of neck where cancer has migrated) for head and neck cancer.

Distinction Made Between Head and Neck Cancers Resulting from Different Risk Factors (03/28/2008)
Recent research indicates that head and neck cancers associated with a certain form of human papillomavirus (HPV) and those not associated with HPV may be linked with different risk factors. Identifying these differing risk factors may further distinguish the two forms of head and neck cancer from each other. These findings were published in the Journal of the National Cancer Institute.

Differences in IMRT Radiation Doses May Complicate Study Results in Head and Neck Cancer (03/20/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in head and neck cancer difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.

HPV-positive Head and Neck Cancers Have Improved Prognosis (02/13/2008)
Patients with head and neck cancer who test positive for the human papillomavirus (HPV) have a better prognosis compared with those who do not have HPV. These results were recently published in the Journal of the National Cancer Institute.

More...

General

Advexin® Improves Survival in Head and Neck Cancer (07/29/2008)
The targeted agent Advexin (p53 tumor suppressor therapy) improves survival compared with methotrexate among head and neck cancer patients with the p53 biomarkers.  These results were recently presented at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine.

Acupuncture Reduces Pain After Surgery for Head and Neck Cancer (06/06/2008)
According to the results of a study presented at the 2008 annual meeting of the American Society of Clinical Oncology, acupuncture is more effective than usual care in reducing pain and dysfunction following neck dissection (surgical removal of lymph nodes on side of neck where cancer has migrated) for head and neck cancer.

Distinction Made Between Head and Neck Cancers Resulting from Different Risk Factors (03/28/2008)
Recent research indicates that head and neck cancers associated with a certain form of human papillomavirus (HPV) and those not associated with HPV may be linked with different risk factors. Identifying these differing risk factors may further distinguish the two forms of head and neck cancer from each other. These findings were published in the Journal of the National Cancer Institute.

Differences in IMRT Radiation Doses May Complicate Study Results in Head and Neck Cancer (03/20/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in head and neck cancer difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.

HPV-positive Head and Neck Cancers Have Improved Prognosis (02/13/2008)
Patients with head and neck cancer who test positive for the human papillomavirus (HPV) have a better prognosis compared with those who do not have HPV. These results were recently published in the Journal of the National Cancer Institute.

More...